June 2026 in “Revista Brasileira de Saúde” This study reviewed current scientific evidence on how scalp microbiome alterations may affect hair growth, citing connections to inflammatory and immune processes and suggesting potential for therapeutic targeting, though further studies are needed to confirm clinical applications.
April 2026 in “Signal Transduction and Targeted Therapy” In a hamster model of COVID-19, this study observed that both low and high doses of testosterone worsened illness in males, while finasteride prevented severe outcomes.
April 2026 in “Portuguese Journal of Dermatology and Venereology” This review summarizes the various skin manifestations linked to COVID-19 infection, vaccination, and personal protective equipment, highlighting their clinical importance and discussing psychological stress and social isolation as additional dermatologic factors.
March 2026 in “Editora Pasteur eBooks” This study conducted a narrative literature review on androgenetic alopecia, highlighting the clinical diagnosis and management strategies, including minoxidil and 5-alpha-reductase inhibitors for men, and antiandrogens for women, along with the use of aesthetic procedures like microneedling as complementary therapies.
March 2026 in “Editora Pasteur eBooks” This study reviews hair follicle physiology and common scalp diseases such as androgenetic alopecia, telogen effluvium, and alopecia areata, highlighting their pathophysiology and current treatment approaches, which may include topical, systemic, and adjunctive therapies.
November 2025 in “Open Repository of the University of Porto (University of Porto)” This report reviews a pharmacy internship experience, presenting activities and two scientific topics, but does not report new research findings.
October 2025 in “Open Repository of the University of Porto (University of Porto)” This report details a six-month pharmacy internship in Portugal, where the author engaged in hospital and community pharmacy settings, and discusses scientific topics including obesity medication risks and alopecia treatment options. Results and conclusions are not explicitly reported.
April 2025 in “Journal of Medical Residency Review” This review examined the use of platelet-rich plasma in aesthetic skin rejuvenation and found promising results when combined with other treatments, but limited efficacy when used alone.
December 2024 in “Open Repository of the University of Porto (University of Porto)” This study consisted of a pharmacy master's thesis detailing practical experiences during a hospital and community pharmacy internship and scientific investigations into the off-label use of dutasteride for androgenetic alopecia and oral vaccines for urinary tract infection prophylaxis, emphasizing therapeutic applications and mechanisms of action.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Tailored medication preparation and ongoing education are crucial for effective treatments.
September 2024 in “World Journal of Advanced Research and Reviews” This review highlights that COVID-19, beyond affecting the respiratory system, leads to various complications across multiple organ systems like cardiovascular, neurological, and immune, emphasizing the importance of understanding these to enhance patient care and guide future research.
July 2024 in “Journal Archives of Health” This study reviewed the medical literature on generalized woolly hair and reported that while there are no effective treatments, some narratives suggest that topical Minoxidil may help with hypotrichosis associated with the condition.
April 2024 in “Cell death and disease” This review discusses the long-term complications of COVID-19, known as long COVID or PASC, and emphasizes the need to improve awareness and management strategies but reports no new clinical findings.
January 2024 in “La Ciencia al Servicio de la Salud y Nutrición” This narrative review attributes antiandrogenic properties to spironolactone, reporting its effectiveness in treating dermatological conditions like alopecia androgenica, acne, and hirsutism, though highlighting necessary attention to potential adverse effects and contraindications.
December 2023 in “Tuberkuloz ve Toraks/Tüberküloz ve toraks” This study identified female sex and specific radiological findings as risk factors for chronic post-COVID syndrome, while long-term use of angiotensin-2 receptor blockers was linked to fewer chronic symptoms.
November 2023 in “Open Repository of the University of Porto (University of Porto)” This summary of a pharmacy internship reports on expanding scientific knowledge through diverse activities, including exploring diabetes medications for obesity treatment and discussing the role of nutritional supplements in geriatrics.
October 2023 in “Peer review” This review discusses the efficacy and safety of using intradermotherapy combined with platelet-rich plasma for treating alopecia and reports no new clinical results.
December 2022 in “International Journal of Biomedicine” This review discusses the potential role of androgens in COVID-19's pathophysiology and their possible link to hair disorders, but reports no new clinical results.
October 2022 in “Southeast Asian journal of health professionals” This article discusses factors influencing hair greying, such as thyroid hormone levels and postmenopausal changes, and suggests lifestyle adjustments for hair health; it reports no new clinical findings.
This review explores the connection between COVID-19 infection and telogen effluvium, highlighting the potential contribution of inflammatory and emotional factors to hair loss; it reports no clinical results.
January 2022 in “Dermatology Review” This study found that patients with chronic kidney disease-associated pruritus had elevated serum levels of interleukin 31, suggesting a possible role of this cytokine in the condition.
In this study, cepharanthine and tetrandrine demonstrated efficacy against SARS-CoV-2 in a cell-based infection assay, with cepharanthine showing a lower IC50 value.
September 2021 in “Revista Interdisciplinar em Saúde” In this observational study, treatment with oral isotretinoin was reported to stabilize hair loss in patients with frontal fibrosing alopecia, offering potential guidance for clinicians on its therapeutic use, with implications for improving affected patients' self-esteem.
September 2021 in “Revista interdisciplinar em saúde” This study reported that oral isotretinoin effectively stabilized frontal fibrosing alopecia in patients, which may help guide healthcare providers in managing this condition related to hair loss and self-esteem.
In this study, researchers found that cosmetic formulations containing guaraná extract effectively controlled oiliness in oily skin and hair by reducing sebaceous gland activity and lipid content without compromising skin barrier function, making them promising for managing excessive sebum production.
June 2020 in “Journal of Dermatological Treatment” This source outlines the potential effects of treatments commonly used in trichology on SARS-CoV-2 infection and offers a guide for managing trichological patients during the COVID-19 era, addressing the challenges of safely visiting and treating patients.
September 2015 in “Actas Dermo-Sifiliográficas” This review covers skin manifestations in chronic kidney disease, highlighting their impact on quality of life, associated prognostic indicators, and available treatments, but provides no new clinical results.
August 2013 in “Pharmacy Today” In a recent study of 15 women with self-perceived hair loss, Viviscal supplementation was associated with an increase in terminal hairs and subjective improvement in hair characteristics.
January 2012 in “Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana)” This study found that SRD5A2 expression is absent in one third of benign adult prostates and is associated with hypermethylation, suggesting potential personalization of treatment for prostatic diseases based on methylation status.
June 2018 in “Actas Dermo-Sifiliográficas” This review discusses recent treatments for androgenetic alopecia, highlighting progress beyond minoxidil to include oral and topical finasteride, dutasteride, and promising adjuvant therapies, but reports no clinical results; the authors emphasize ongoing research and potential new options.